



Express Mail No.: EL 452 480 864 US

#14
Supp
JDS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Kozikowski *et al.*

Serial No.: 09/246,307

Group Art Unit: 1653

Filed: February 8, 1999

Examiner: Gupta, A.

For: CYCLIC DIPEPTIDES AND
AZETIDINONE COMPOUNDS AND THEIR
USE IN TREATING CNS INJURY AND
NEURODEGENERATIVE DISORDERS

Attorney Docket No.: 9328-009-999

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure provisions of 37 C.F.R. §1.56, there is hereby provided certain information which the Examiner may consider material to the examination of the subject U.S. patent application. It is requested that the Examiner make this information of record if it is deemed material to the examination of the application.

1. Enclosures accompanying this Information Disclosure Statement are:

- 1a. ☒ A list of all patents, publications, applications, or other information submitted for consideration by the office.
- 1b. A legible copy of :
 - ☐ Each U.S. patent application publication and U.S. and foreign patent;
 - ☒ Each publication or that portion which caused it to be listed on the PTO-1449;
 - ☐ For each cited pending U.S. application, the application specification including the claims, and any drawing of the application, or portion of the application which caused it to be listed on the PTO-1449 including any claims directed to that portion;
 - ☐ all other information or portion which caused it to be listed on the PTO-1449.
- 1c. ☐ An English language copy of search report(s) from a counterpart foreign application or PCT International Search Report.

- 1d. ☐ Explanations of relevancy (ATTACHMENT 1(d), hereto) or English language abstracts of the non-English language publications.
2. ☐ This Information Disclosure Statement is filed under 37 C.F.R. §1.97(b):
- ☐ Within three months of the filing date of a national application other than a continued prosecution application under §1.53(d);
 - ☐ Within three months of the date of entry of the national stage as set forth in §1.491 in an international application;
 - ☐ Before the mailing of the first Office action on the merits;
 - ☐ Before the mailing of a first Office action after the filing of a request for continued examination under §1.114.
3. ☒ This Information Disclosure Statement is filed under 37 C.F.R. §1.97(c) after the period specified in 37 C.F.R. §1.97(b), but before the mailing date of any of a final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311 or an action that otherwise closes prosecution in the application.

(Check either Item 3a or 3b)

- 3a. ☐ The Certification Statement in Item 5 below is applicable. Accordingly, no fee is required.
- 3b. ☒ The \$180.00 fee set forth in 37 C.F.R. §1.17(p) in accordance with 37 C.F.R. §1.97(c) is:
- ☐ enclosed
 - ☒ to be charged to Pennie & Edmonds LLP Deposit Account No. 16-1150.

(Item 3b to be checked if any reference known for more than 3 months)

4. ☐ This Information Disclosure Statement is filed under 37 C.F.R. §1.97(d) after the period specified in 37 C.F.R. §1.97(c), but on or before the date of payment of the issue fee.

The \$180.00 fee set forth in 37 C.F.R. §1.17(i)(1) is:

- ☐ enclosed.
- ☐ to be charged to Pennie & Edmonds LLP Deposit Account No. 16-1150.

The Certification Statement in Item 5 below is applicable.

5. ☐ Certification Statement *(applicable if Item 3a or Item 4 is checked)*

(Check either Item 5a or 5b)

- 5a. ☐ In accordance with 37 C.F.R. §1.97(e)(1), it is certified that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

- 5b. ☐ In accordance with 37 C.F.R. §1.97(e)(2), it is certified that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned after making reasonable inquiry, was known by any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.
6. ☐ This application is a continuation application under 37 C.F.R. §1.60 or §1.53(b) or (d).

(Check appropriate Items 6a, 6b and/or 6c)

- 6a. ☐ A Petition to Withdraw from issue under 37 C.F.R. §1.313(b)(5) is concurrently filed herewith.
- 6b. ☐ Copies of publications listed on Form PTO-1449 from prior application Serial No. __, filed on __, of which this application claims priority under 35 U.S.C. §120, are not being submitted pursuant to 37 C.F.R. §1.98(d).
- 6c. ☐ Copies of the publications listed on Form PTO-1449 were not previously cited in prior application Serial No. __, filed on __, and are provided herewith.
7. ☐ This is a Supplemental Information Disclosure Statement. *(Check either Item 7a or 7b)*
- 7a. ☐ This Supplemental Information Disclosure Statement under 37 C.F.R. §1.97(f) supplements the Information Disclosure Statement filed on __. A bona fide attempt was made to comply with 37 C.F.R. §1.98, but inadvertent omissions were made. These omissions have been corrected herein. Accordingly, additional time is requested so that this Supplemental Information Disclosure Statement can be considered as if properly filed on __.
- 7b. ☐ This Supplemental Information Disclosure Statement is timely filed within one (1) month of a PTO Notice under 37 C.F.R. §1.97(i).
8. ☐ In accordance with 37 C.F.R. §1.98, a concise explanation of what is presently understood to be the relevance of each non-English language publication is:

(Check Item 8a, 8b, or 8c)

- 8a. ☐ satisfied because all non-English language publications were cited on the enclosed English language copy of the PCT International Search Report or the search report from a counterpart foreign application indicating the degree of relevance found by the foreign office.
- 8b. ☐ set forth in the application.
- 8c. ☐ enclosed as an attachment hereto.
9. ☒ The Commissioner is authorized to charge any additional fee required or credit any overpayment for this Information Disclosure Statement and/or Petition to Pennie & Edmonds LLP Deposit Account No. 16-1150.




10.


No admission is made that the information cited in this Statement is, or is considered to be, material to patentability nor a representation that a search has been made (other than a search report of a foreign counterpart application or PCT International Search Report if submitted herewith). 37 C.F.R. §§1.97(g) and (h).

Respectfully submitted,

Date 7/11/01

 45,298
Sunil K. Singh (Reg. No.)

For Samuel B. Abrams (Reg. No. 30,605)
PENNIE & EDMONDS LLP
1155 Avenue of Americas
New York NY 10036-2720
(212) 790 - 9090

 LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)					ATTY. DOCKET NO.		APPLICATION NO.		
					9328-009-999		09/246,307		
					APPLICANT				
					Feder				
					FILING DATE		GROUP		
					February 8, 1999		1653		
U.S. PATENT DOCUMENTS									
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
FOREIGN PATENT DOCUMENTS									
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
							YES	NO	
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)									
		La Ferla <i>et al.</i> , "The Alzheimer's $\alpha\beta$ peptide induces neurodegeneration and apoptotic cell death in transgenic mice", <i>Nature Genetics</i> 1995, 9, 21-30							✓
		Eldadah <i>et al.</i> , "The Role of CED-3-Related Cysteine Proteases in Apoptosis of Cerebellar Granule Cells", <i>J. Neuroscience</i> 1997, 17 (16), 6105-6113							
		Su <i>et al.</i> , "Immunohistochemical evidence for apoptosis in Alzheimer's disease", <i>NeuroReport</i> 1994, 5, 2529-2533							
		Smucker, "Maximizing Function in Alzheimer's Disease: What Role for Tacrine", <i>American Family Physician</i> 1996, 645-652							
		Ott <i>et al.</i> , "Complementary and Alternative Medicines for Alzheimer's Disease", <i>J. of Geriatric Psychiatry and Neurobiology</i> 1998, 11, 163-173							
		Ruther <i>et al.</i> , "Sustained improvements in patients with dementia of Alzheimer's type (DAT) 6 months after termination of Cerebrolysin therapy", <i>J. Neural Transmission</i> 2000, 107, 815-829							
		Nalbantoglu <i>et al.</i> , "Impaired learning and LTP in mice expressing the carboxy terminus of the Alzheimer amyloid precursor protein", <i>Nature</i> 1997, 387, 500-505							
		Hsiao <i>et al.</i> , "Correlative Memory Deficits, $\alpha\beta$ Elevation, and Amyloid Plaques in Transgenic Mice", <i>Science</i> 1996, 274, 99-102							
		D'Hooge <i>et al.</i> , "Spatial learning deficit in mice expressing human 751-amino acid β -amyloid precursor protein", <i>NeuroReport</i> 1996, 2807-2811							
		Graves <i>et al.</i> , "The Association between Head Trauma and Alzheimer's Disease", <i>American J. Epidemiology</i> 1990, 131(3), 491-501							
		Plassman <i>et al.</i> , "Documented hear injury in early adulthood and risk of Alzheimer's disease and other dementias", <i>Neurology</i> 2000, 55, 1158							
EXAMINER					DATE CONSIDERED				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609 ; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.									